News
Overview of research on ‘general’ policies aimed at generics in 2012
2013-02-01 Period: January to August 2012 Many governments around the world already have policies in place to promote the use of generic medicines, and with the… Read More »
Biosimilars approved and marketed in Germany
2013-01-30 Last updated: 23 November 2012 The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) is responsible for the approval, i.e.… Read More »
Major shake-up of API import rules in Europe
2013-01-28 EU is seeking to impose good manufacturing practice (GMP) standards throughout the world in an attempt to stop the import of counterfeit or substandard active… Read More »
ABPI issues position paper on biosimilars
2013-01-25 The Association of the British Pharmaceutical Industry (ABPI), which represents innovative research-based biopharmaceutical companies in the UK, announced on 12 November 2012 the publication of… Read More »
Pharmaceutical trade barriers are falling
2013-01-23 The European Parliament has voted in favour of a trade pact between Israel and the European Union (EU) that will allow easier access to medicines… Read More »
Biosimilar policies in Spain
2013-01-21 Spain is Europe’s fifth largest pharmaceutical market, however, in 2009, biosimilars accounted for less than 5% of the total biologicals market. The Spanish Agency for… Read More »
German court rules Seroquel XR patent invalid
2013-01-18 AstraZeneca has lost another battle to protect its blockbuster anti-psychotic drug Seroquel (quetiapine fumarate) against generics. The pharma giant announced on 13 November 2012 that… Read More »
Dialogue needed to build confidence in biosimilars
2013-01-16 Concerns about the safety and efficacy of biosimilars have led many healthcare professionals to become reluctant to prescribe these products for their patients. According to… Read More »
Saving money in the European healthcare system with biosimilars
2013-01-14 Biotechnology-derived medicines are increasingly popular for treating a range of conditions from cancer to autoimmunity, and yet they are among the most expensive healthcare products… Read More »
The latest biosimilars agreements
2013-01-11 Biosimilar is still the hottest subject around. Just a few of the latest collaborations for the development of biosimilars include agreements made on 6 November… Read More »
